 This study proposes a novel stealthy nanovehicle system for targeted delivery of chemotherapeutic drugs to tumors. The nanovehicle consists of anti-CD11B conjugated bovine serum albumin, BSA, nanoparticles loaded with the cytobine, which are camouflaged by neutrophils to improve their ability to penetrate into tumors. Once inside the tumor, the fluorescent signal molecule, IR820, allows for tracking the precise location of the nanovehicle. Additionally, the release of cytobine from the BSA nanoparticle leads to activation of gastrimony, which triggers pyroptosis, leading to improved adaptive immunity against the tumor. This system was tested in a triple-negative breast cancer mouse model and demonstrated successful tumor targeting and immunotherapy. This article was authored by Xu Yiyu, Guizheng Xing, Xu Peixing, and others.